Streetbeat News

Revenues

ABT

Abbott Laboratories (NYSE: ABT) reported Q2 earnings with revenue and profit beating estimates. The company raised its annual profit guidance due to strong growth in Medical Devices. Despite a decline in COVID-19 testing sales, other segments like Nutrition and Medical Devices showed significant growth. Abbott also announced FDA approval for new glucose monitoring systems and ten new growth opportunities from its pipeline.

Portfolio Pulse from Vandana Singh

July 18, 2024 | 1:54 pm

MBGYY

RIO

STLA

Mercedes-Benz Group AG and Stellantis NV are in discussions with the Serbian government to invest in lithium-processing and EV battery production. This initiative aims to develop a comprehensive lithium industry in Serbia, reducing Europe's reliance on Asian imports. Despite a slowdown in EV adoption, this project could boost Serbia's economic growth and technological advancements.

Portfolio Pulse from Shivani Kumaresan

July 18, 2024 | 1:27 pm

EWQ

FEZ

FXE

The European Central Bank (ECB) kept its key interest rates unchanged at its July meeting, aligning with market expectations. The ECB did not provide specific guidance on future policy, slightly chilling market expectations for a September rate cut. The euro held steady against the U.S. dollar, and European equity markets rose, with France's CAC 40 index being the top performer.

Portfolio Pulse from Piero Cingari

July 18, 2024 | 1:18 pm

F

GM

RIVN

TSLA

Tesla's Cybertruck outsold Ford's F-150 Lightning and Rivian's R1T in May, despite its higher price. Tesla registered 3,907 Cybertrucks, compared to 2,353 F-150 Lightnings and 1,237 R1Ts. General Motors' electric trucks had significantly lower registrations. Tesla is ramping up production to meet high demand.

Portfolio Pulse from Anan Ashraf

July 18, 2024 | 1:15 pm

MARA

Marathon Digital Holdings Inc (NASDAQ:MARA) is trading higher after a recent dip, driven by a rebound in Bitcoin prices and positive inflows into Bitcoin spot ETFs. The company is set to report its Q2 financial results on Aug. 1, with expected losses and revenue projections. Marathon's Bitcoin production decreased year-over-year, but its operational hashrate and total Bitcoin holdings have increased.

Portfolio Pulse from Adam Eckert

July 18, 2024 | 1:15 pm

WLDN

Willdan Group has successfully completed energy efficiency projects for a Pacific Northwest data center, achieving over 4.1 million kWh in annual savings and reducing peak load by 475 kW. The project also secured $1.7 million in incentives for early replacement of uninterruptible power supply systems, all without causing any data center downtime.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 1:13 pm

ANSS

NVDA

SMCI

Ansys collaborates with Supermicro and NVIDIA to deliver turnkey hardware for multiphysics simulation, boosting speeds up to 1,600x. This partnership aims to reduce time-to-market and enhance design exploration across various industries.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 1:10 pm

GRAL

GRAIL, Inc. (NASDAQ:GRAL) has enrolled the first participant in the REACH study to evaluate the clinical impact of its Galleri multi-cancer early detection test in the Medicare population. The study, conducted by Community Health Network, aims to assess the real-world impact of Galleri in addition to current cancer screenings, with a focus on diverse and underrepresented populations. Medicare will cover the costs for participants.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 1:08 pm

AMZN

Amazon's Prime Day 2024 set new records with massive sales, extensive deals, and the introduction of an AI-powered assistant. Independent sellers sold over 200 million items, and Prime members saved billions globally. The event featured exclusive deals, fast delivery options, and a wide range of entertainment and shopping benefits.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 1:07 pm

NVS

Novartis AG (NYSE:NVS) reported strong Q2 earnings with an adjusted EPS of $1.97, beating the consensus of $1.89. Revenue reached $12.51 billion, driven by key drugs like Entresto and Cosentyx. The company raised its 2024 profit forecast and expects core operating income to grow in the mid-to-high-teens percentage range.

Portfolio Pulse from Vandana Singh

July 18, 2024 | 1:06 pm